Isoniazid mono-resistance negatively affects tuberculosis treatment outcomes in Europe Source: International Congress 2018 – New developments in tuberculosis Year: 2018
A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis Source: Eur Respir J, 50 (4) 1701696; 10.1183/13993003.01696-2017 Year: 2017
Detection of fluoroquinolones resistance mutations in mycobacterium tuberculosis by hydrolysis probes and RFLP Source: Annual Congress 2013 –Diagnostic features of tuberculosis II Year: 2013
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Resistance to pyrazinamide of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 413s Year: 2007
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Evaluation of a molecular assay for detection of rifampin and isoniazid resistant mycobacterium tuberculosis in strains and clinical samples Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020
Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001
Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004
Treatment outcomes of tuberculosis (TB) patients with rifampin (RMP) or RMP and isoniazid (INH) resistance receiving standard regimen Source: Eur Respir J 2003; 22: Suppl. 45, 42s Year: 2003
Characteristics of drug susceptibility testing for bedaquline and clofazimine of 178 drug-resistant Mycobacterium tuberculosis isolates in Japan Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019
Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013